Guidelines of care for the management of atopic dermatitis in adults with topical therapies

BackgroundNew evidence has emerged since the 2014 guidelines that further informs the management of AD with topical therapies. These guidelines update the 2014 recommendations for management of atopic dermatitis (AD) with topical therapies.ObjectiveTo provide evidence-based recommendations related to management of AD in adults using topical treatments.MethodsA multidisciplinary workgroup conducted a systematic review and applied the …

Continue reading Guidelines of care for the management of atopic dermatitis in adults with topical therapies

Prenatal antibiotic exposure, asthma and the atopic march: A systematic review and meta-analysis

BackgroundAntibiotic use during pregnancy may increase the risk for asthma in children. We performed a meta-analysis assessing prenatal antibiotic exposure and the risk for childhood wheeze or asthma, as well as for diseases associated with the atopic march. MethodsA systematic literature search protocol (PROSPERO-ID: CRD42020191940) was registered and searches were completed using Medline, Proquest, Embase, …

Continue reading Prenatal antibiotic exposure, asthma and the atopic march: A systematic review and meta-analysis

Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies

Interleukin (IL)-31 affects the inflammatory response, is involved in epidermal barrier disruption in atopic dermatitis (AD) and plays a key role in pruritus. Nemolizumab, a humanized monoclonal antibody against IL-31 receptor A, reduced pruritus in patients with AD after a 16-week administration period. ObjectivesTo examine the long-term effectiveness and safety of nemolizumab in patients aged …

Continue reading Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies

Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK)

Risk factors for severe COVID-19 include older age, male sex, obesity, black or Asian ethnicity and underlying medical conditions. Whether these factors also influence susceptibility to developing COVID-19 is uncertain. Methods We undertook a prospective, population-based cohort study (COVIDENCE UK) from 1 May 2020 to 5 February 2021. Baseline information on potential risk factors was …

Continue reading Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK)

Association Between #Atopic Eczema and #Cancer in England and Denmark

Associations between atopic eczema and cancer are unclear, with competing theories that increased immune surveillance decreases cancer risk and that immune stimulation increases cancer risk. Establishing baseline cancer risk in people with atopic eczema is important before exploring the association between new biologic drugs for atopic eczema and cancer risk.. ..In England, matched cohorts included …

Continue reading Association Between #Atopic Eczema and #Cancer in England and Denmark